ACM
ARQT icon

ACT Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

ACT Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,000
Closed -$328K – 111
2021
Q2 		$328K Buy
+12,000
New +$338K 0.17% 75

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACT Capital Management's ARQT Position: Q3 2021 in Review

ACT Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2021, closing a stake of 12,000 shares — an estimated $328K sold.

ACT Capital Management first reported a position in ARQT in Q2 2021 and held it in 1 quarter. The position peaked at $328K in Q2 2021. 103 funds tracked by Wall St. Rank hold ARQT as of Q3 2021.

  • ACT Capital Management reported no remaining Arcutis Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 12,000 Arcutis Biotherapeutics shares in Q3 2021, an estimated $328K.
  • ACT Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Arcutis Biotherapeutics position peaked at $328K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.